Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool

European Journal of Immunology

Volumn 42, Issue 12, 2012, Pages 3167-3173

  Fiebiger, Benjamin M ^a   Moosmann, Andreas ^b,c   Behrends, Uta ^a   Mautner, Josef ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Antigen presentation; Epstein Barr virus; MHC class I; Protein stability; T lymphocyte

Indexed keywords

DOXYCYCLINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; ENZYME DEGRADATION; EPSTEIN BARR VIRUS; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TARGETING;

ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TIME FACTORS; VIRAL PROTEINS;

EID: 84871267539     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242627     Document Type: Article

References (24)

1. Kloetzel, P. M., Generation of major histocompatibility complex class i antigens: functional interplay between proteasomes and tppii. Nat. Immunol. 2004. 5: 661-669.
2. Esquivel, F., Yewdell, J. and Bennink, J., Rma/s cells present endogenously synthesized cytosolic proteins to class i-restricted cytotoxic t lymphocytes. J. Exp. Med. 1992. 175: 163-168.
3. Yewdell, J. W., Anton, L.C. and Bennink, J. R., Defective ribosomal products (drips): a major source of antigenic peptides for mhc class i molecules? J. Immunol. 1996. 157: 1823-1826.
4. Yewdell, J. W., Drips solidify: progress in understanding endogenous mhc class i antigen processing. Trends Immunol. 2011. 32: 548-558.
5. Qian, S. B., Reits, E., Neefjes, J., Deslich, J. M., Bennink, J. R. and Yewdell, J. W., Tight linkage between translation and mhc class i peptide ligand generation implies specialized antigen processing for defective ribosomal products. J. Immunol. 2006. 177: 227-233.
6. Reits, E. A., Vos, J. C., Gromme, M. and Neefjes, J., The major substrates for tap in vivo are derived from newly synthesized proteins. Nature 2000. 404: 774-778.
7. Khan, S., de Giuli, R., Schmidtke, G., Bruns, M., Buchmeier, M., van den Broek, M. and Groettrup, M., Cutting edge: neosynthesis is required for the presentation of a T-cell epitope from a long-lived viral protein. J. Immunol. 2001. 167: 4801-4804.
8. Cardinaud, S., Starck, S. R., Chandra, P. and Shastri, N., The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS ONE 2010. 5: e8692.
9. Schubert, U., Anton, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W. and Bennink, J. R., Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000. 404: 770-774.
10. Dolan, B. P., Bennink, J. R. and Yewdell, J. W., Translating drips: progress in understanding viral and cellular sources of mhc class i peptide ligands. Cell. Mol. Life Sci. 2011. 68: 1481-1489.
11. Apcher, S., Manoury, B. and Fahraeus, R., The role of mrna translation in direct mhc class i antigen presentation. Curr.Opin. Immunol. 2012. 24: 71-76.
12. Lev, A., Takeda, K., Zanker, D., Maynard, J. C., Dimberu, P., Waffarn, E., Gibbs, J. et al., The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity 2008. 28: 787-798.
13. Yen, H. C., Xu, Q., Chou, D. M., Zhao, Z. and Elledge, S. J., Global protein stability profiling in mammalian cells. Science 2008. 322: 918-923.
14. Berglund, P., Finzi, D., Bennink, J. R. and Yewdell, J. W., Viral alteration of cellular translational machinery increases defective ribosomal products. J. Virol. 2007. 81: 7220-7229.
15. + T-cell immunosurveillance. J. Immunol. 2011. 186: 2065-2072.
16. Engelhard, V. H., Altrich-Vanlith, M., Ostankovitch, M. and Zarling, A. L., Post-translational modifications of naturally processed mhc-binding epitopes. Curr. Opin. Immunol. 2006. 18: 92-97.
17. + T helper cells. Eur. J. Immunol. 2004. 34: 2500-2509.
18. Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G. and Wandless, T. J., A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 2006. 126: 995-1004.
19. Bornkamm, G. W., Berens, C., Kuklik-Roos, C., Bechet, J. M., Laux, G., Bachl, J., Korndoerfer, M. et al., Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res. 2005. 33: e137.
20. Sugawara, S., Abo, T. and Kumagai, K., A simple method to eliminate the antigenicity of surface class i mhc molecules from the membrane of viable cells by acid treatment at ph 3. J. Immunol. Methods 1987. 100: 83-90.
21. Dolan, B. P., Sharma, A. A., Gibbs, J. S., Cunningham, T. J., Bennink, J. R. and Yewdell, J. W., Mhc class i antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mrna. Proc. Natl. Acad. Sci. USA 2012. 109: 7025-7030.
22. Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J., Daemen, T. and Nijman, H. W., Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J. Biomed. Biotechnol. 2011. 2011: 702146.
23. Brosh, R. and Rotter, V., When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009. 9: 701-713.
24. Nimmerjahn, F., Milosevic, S., Behrends, U., Jaffee, E. M., Pardoll, D. M., Bornkamm, G. W. and Mautner, J., Major histocompatibility complex class ii-restricted presentation of a cytosolic antigen by autophagy. Eur. J. Immunol. 2003. 33: 1250-1259.